Semaglutide and Heart Health: What Houston Patients Should Know
Semaglutide does more than lower the number on the scale. Here's what the clinical data says about heart health, and what it means for Houston patients managing obesity and cardiovascular risk.
Reviewed for accuracy against current FDA guidance, peer-reviewed clinical trial data (STEP, SURMOUNT trials), and manufacturer prescribing information. See our editorial standards.
Semaglutide cuts major cardiovascular events — heart attack, stroke, cardiovascular death — by roughly 20% in high-risk patients, according to the SELECT trial. That's not a side benefit; it's a primary finding from one of the largest weight loss drug trials ever run, and it's reshaping how Houston cardiologists and weight loss clinics think about GLP-1 treatment. Wegovy and Ozempic are the same molecule at different doses, and the cardiovascular data applies across both. Here's what the trial results actually show, where the evidence has limits, and what Houston patients with existing heart disease or obesity-related risk factors should discuss with their provider before starting semaglutide.
1What Semaglutide Actually Is
Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after you eat. It tells your pancreas to release insulin, tells your liver to slow glucose production, and signals your brain that you are full. Semaglutide mimics that hormone, but it lasts much longer in your body than the natural version. You inject it once a week. The FDA approved semaglutide 0.5 mg and 1 mg (Ozempic) in 2017 for type 2 diabetes. In 2021, the FDA approved a higher 2.4 mg dose (Wegovy) specifically for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. Those are two separate approvals, two separate products, and two different dosing schedules. Your Houston prescriber will choose based on your specific diagnosis and insurance coverage. Understanding this distinction matters because insurance carriers like Blue Cross Blue Shield of Texas and Aetna often cover one but not the other depending on your plan.
2The STEP Trials: What the Weight Loss Data Actually Says
The STEP (Semaglutide Treatment Effect in People with Obesity) trials were a series of global phase 3 clinical trials that tested Wegovy at the 2.4 mg dose. STEP 1, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity or overweight plus a weight-related condition. Participants who used semaglutide lost an average of 14.9% of their body weight over 68 weeks. The placebo group lost about 2.4%. That is a meaningful gap. STEP 2 focused specifically on adults with type 2 diabetes. Those participants lost an average of 9.6% of body weight. STEP 3 combined semaglutide with intensive behavioral therapy and found even greater average losses of around 16%. STEP 4 looked at what happens when people stop. Weight came back quickly, which tells you this is a long-term treatment, not a short course. For Houston patients carrying 50, 80, or 100 extra pounds, a 15% reduction translates to real changes in blood pressure, cholesterol, and cardiovascular strain.
3The SELECT Trial: The Heart Health Breakthrough
The SELECT trial is the most important cardiovascular study of semaglutide to date. It was published in the New England Journal of Medicine in November 2023. The trial enrolled 17,604 adults across 41 countries. All participants had established cardiovascular disease and a BMI of 27 or above. None had diabetes. Participants received either semaglutide 2.4 mg weekly or a placebo for an average of about 3.3 years. The primary outcome was a composite of death from cardiovascular causes, nonfatal heart attack, or nonfatal stroke. Semaglutide reduced that composite risk by 20% compared to placebo. That is a statistically significant result. Cardiovascular death alone was reduced by 15%. Nonfatal heart attacks dropped by 28%. Based on these findings, the FDA in March 2024 approved Wegovy specifically to reduce the risk of serious cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Houston patients who already have heart disease and obesity may now have a stronger case for insurance coverage as a result.
4How Semaglutide Affects Blood Pressure, Cholesterol, and Inflammation
Weight loss alone does not fully explain the cardiovascular benefits seen in SELECT. Researchers believe semaglutide has direct effects on the cardiovascular system beyond just reducing body weight. In clinical trials, semaglutide consistently lowered systolic blood pressure by an average of about 3 to 6 mmHg. That may sound small, but at a population level it matters. Triglycerides dropped significantly in most studies. LDL cholesterol saw modest improvements. C-reactive protein, a marker of systemic inflammation, also fell. Inflammation is a major driver of atherosclerosis, which is the buildup of plaque in artery walls that leads to heart attacks and strokes. Houston has a high prevalence of metabolic syndrome, a cluster of conditions that includes high blood pressure, high triglycerides, low HDL cholesterol, high fasting blood sugar, and abdominal obesity. Semaglutide addresses several of those markers at once. That is part of why cardiologists across the Texas Medical Center are increasingly involved in GLP-1 prescribing decisions, not just endocrinologists and primary care physicians.
5Who in Houston Is a Good Candidate
Not every patient at a Houston weight loss clinic will have the same risk profile. Your cardiovascular history shapes whether semaglutide is simply a weight loss tool or also a medication with a proven mortality benefit for you specifically. The SELECT trial included patients with established cardiovascular disease, meaning a prior heart attack, prior stroke, or documented peripheral arterial disease. If you fall into that category and your BMI is 27 or above, you now have FDA-approved cardiovascular indication data behind you. That can matter when talking to insurers like UnitedHealthcare or Cigna about coverage. If you do not have established cardiovascular disease but you do have risk factors like hypertension, prediabetes, or sleep apnea, semaglutide can still be prescribed for weight management under the original Wegovy approval. Patients at clinics along the Katy Freeway corridor, in Sugar Land, Pearland, or The Woodlands should ask their physician specifically which FDA indication applies to their case. That question can affect your prescription, your dosing timeline, and your insurance paperwork.
6Side Effects Houston Patients Report Most Often
Semaglutide's most common side effects are gastrointestinal. Nausea is the most frequently reported, especially during the dose escalation phase in the first three to five months. Vomiting, diarrhea, and constipation also occur. In the STEP 1 trial, about 44% of semaglutide participants reported nausea compared to 16% in the placebo group. Most people describe the nausea as manageable, particularly when they eat smaller meals and avoid high-fat foods. Houston's food culture, which leans toward large portions and rich barbecue or Tex-Mex, can make early semaglutide adjustments harder. Physicians at local clinics often advise patients to start with smaller servings of familiar foods rather than attempting a full diet overhaul at the same time as dose escalation. More serious but rare risks include pancreatitis, gallbladder disease, and a theoretical risk of thyroid C-cell tumors seen in rodent studies. Semaglutide carries a black box warning about thyroid cancer, though it has not been confirmed in humans. If you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, semaglutide is contraindicated. Your prescriber should take a full family history before starting you on treatment.
7Talking to Your Houston Doctor and Working through Insurance
Getting semaglutide covered in Texas takes preparation. Many Houston patients have found that prior authorization is required by most major carriers, including Blue Cross Blue Shield of Texas, Aetna, Cigna, and UnitedHealthcare. Your doctor's office will typically submit documentation of your BMI, any comorbid conditions, and your cardiovascular history. If you have established cardiovascular disease and qualify under the SELECT-based indication, include that documentation explicitly. Some clinics in the Heights, Midtown, and Cypress have dedicated staff who handle GLP-1 prior authorizations regularly and know what each payer needs. If you are denied, appeals succeed more often than patients expect, especially when cardiovascular indications are clearly documented. For patients without coverage, Novo Nordisk offers a savings card for commercially insured patients that can reduce the out-of-pocket cost significantly. Compounded semaglutide from unregulated pharmacies is a different story. The FDA has raised safety concerns about those products, and the clinical trial data supporting cardiovascular benefit applies only to FDA-approved semaglutide at verified doses and purity.
8What to Ask at Your First Appointment
Walking into a Houston weight loss clinic prepared saves time and frustration. Before your first appointment, gather your most recent labs, any cardiology records, and a list of your current medications. Some medications interact with semaglutide, including insulin and other diabetes drugs that can increase hypoglycemia risk when combined. At the appointment, ask your physician which FDA indication applies to you specifically, whether your cardiovascular history qualifies you for the SELECT-based approval, what the full dose escalation schedule looks like, how they manage GI side effects, and what monitoring they recommend during treatment. Ask about their protocol if you experience chest pain, significant vomiting, or severe abdominal pain, which can signal pancreatitis. Clinics affiliated with larger health systems like Houston Methodist, Memorial Hermann, or UTHealth typically have cardiology referral pathways built in. Standalone weight loss clinics vary. Know before you commit whether your prescriber can coordinate care with a cardiologist if your heart history makes that necessary.
Semaglutide is the most studied weight loss medication in history, and the cardiovascular data from SELECT is genuinely meaningful for Houston patients who carry both obesity and heart disease. It is not a cure and it is not right for everyone. But for the right patient with the right physician, it can reduce the risk of a heart attack or stroke while helping shed significant weight. Use our Houston Weight Loss Directory to find a physician-supervised clinic near you that has experience prescribing GLP-1 medications safely.
Sources & References
Clinical data referenced in this article is drawn from the FDA drug database, peer-reviewed publications (STEP trials, SURMOUNT trials), and manufacturer prescribing information for Wegovy, Ozempic, Zepbound, and Mounjaro. Pricing figures reflect publicly available estimates and may vary. Insurance coverage information is general guidance — confirm your specific benefits with your plan.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed physician before starting any weight loss medication or program.